Literature DB >> 347569

[Double-blind study on the anti-convulsive effect of phenobarbital and valproate in the Lennox syndrome].

F Vassella, A Rüdeberg, V Da Silva, E Pavlincova.   

Abstract

In a double-blind crossover trial valproate was compared with phenobarbital with regard to anticonvulsive activity and tolerance in 17 epileptic children (mean age 55 +/- 26 months) with Lennox syndrome. Valproate in association with a phenobarbital dose reduced by about 40% proved to be to a statistically significant degree more active against epileptic seizures than phenobarbital alone. No difference in the effect on the EEG tracings was observed. Valproate appeared to be somewhat more active than phenobarbital with regard to behaviour, but the difference was not significant. Tolerance to both products was equally good.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 347569

Source DB:  PubMed          Journal:  Schweiz Med Wochenschr        ISSN: 0036-7672


  6 in total

Review 1.  Treatment of Lennox-Gastaut syndrome.

Authors:  Eleanor C Hancock; J Helen Cross
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

2.  New treatment options for lennox-gastaut syndrome.

Authors:  Monica E Lemmon; Eric H Kossoff
Journal:  Curr Treat Options Neurol       Date:  2013-08       Impact factor: 3.598

Review 3.  Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy.

Authors:  Wolfgang Löscher
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 4.  Drug treatment of epilepsy. Outlines, criticism and perspectives.

Authors:  E Beghi; R Di Mascio; G Tognoni
Journal:  Drugs       Date:  1986-03       Impact factor: 9.546

5.  Anti-seizure medications for Lennox-Gastaut syndrome.

Authors:  Francesco Brigo; Katherine Jones; Christin Eltze; Sara Matricardi
Journal:  Cochrane Database Syst Rev       Date:  2021-04-07

6.  Treatment of Lennox-Gastaut syndrome: overview and recent findings.

Authors:  Kenou van Rijckevorsel
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.